CYKLOKAPRON Drug Patent Profile
✉ Email this page to a colleague
When do Cyklokapron patents expire, and when can generic versions of Cyklokapron launch?
Cyklokapron is a drug marketed by Pfizer and Pharmacia And Upjohn and is included in two NDAs.
The generic ingredient in CYKLOKAPRON is tranexamic acid. There are eight drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the tranexamic acid profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cyklokapron
A generic version of CYKLOKAPRON was approved as tranexamic acid by AM REGENT on August 10th, 2011.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CYKLOKAPRON?
- What are the global sales for CYKLOKAPRON?
- What is Average Wholesale Price for CYKLOKAPRON?
Summary for CYKLOKAPRON
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 258 |
| Clinical Trials: | 54 |
| Patent Applications: | 3,097 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for CYKLOKAPRON |
| What excipients (inactive ingredients) are in CYKLOKAPRON? | CYKLOKAPRON excipients list |
| DailyMed Link: | CYKLOKAPRON at DailyMed |
Recent Clinical Trials for CYKLOKAPRON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Northwestern University | Phase 3 |
| Karolinska Institutet | Phase 4 |
| University of Cape Town | Phase 4 |
Pharmacology for CYKLOKAPRON
| Drug Class | Antifibrinolytic Agent |
| Physiological Effect | Decreased Fibrinolysis |
US Patents and Regulatory Information for CYKLOKAPRON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | CYKLOKAPRON | tranexamic acid | INJECTABLE;INJECTION | 019281-001 | Dec 30, 1986 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pharmacia And Upjohn | CYKLOKAPRON | tranexamic acid | TABLET;ORAL | 019280-001 | Dec 30, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CYKLOKAPRON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | CYKLOKAPRON | tranexamic acid | INJECTABLE;INJECTION | 019281-001 | Dec 30, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| Pharmacia And Upjohn | CYKLOKAPRON | tranexamic acid | TABLET;ORAL | 019280-001 | Dec 30, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CYKLOKAPRON
See the table below for patents covering CYKLOKAPRON around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
